

CURRICULUM VITAE

JOHN RICHARD THORNBACK

A globally experienced senior Board level executive with particular expertise in

- **Identifying and enabling strategy for start-up companies**
- **Streamlining existing organisations to leverage commercial value**
- **Overseeing the change from public to private company.**
- **CEO of companies in Asia, Europe and N. America.**
- **Raising money in N. America, Asia and Europe.**
- **Identifying value of new opportunities that have potential to move businesses to a new level**
- **Operational expertise in commercial and development functions**

Career Summary

23+ years of diagnostic industry experience in executive management, including CEO positions. Raised start up funding for three companies. Changed large public research centres to successful private enterprises by maintaining academic excellence but delivering commercial targets. Created senior management teams in both N.America, Singapore and Europe. Managed companies through to exit, including trade sale and JV. Identified, negotiated and implemented key commercial partnerships and technology licencing deals that radically improved the businesses and developed healthy pipelines of products. Established route to market through global commercial networks.

A non executive director of commercial and government enterprises since 2004. Member of Scientific Advisory Boards and professional organisations maintaining strong links and networks to academic and scientific communities.

PROFESSIONAL CAREER

6/2006- present

Title: **Founder and Chair**

Company: Sestria Ltd

- Sestria advises diagnostic companies on all aspects of diagnostic development with particular focus on molecular diagnostics and specialist expertise in product development, FDA and CE regulatory requirements and market introduction strategies.
- Sestria has worked with a wide range of clients from universities to small start ups to large multinational diagnostic companies.

09/13-08/16

Title: **Managing Director**

Company: Apta Biosciences Pte Ltd

- Apta is a newly established spin off from Fujitsu Laboratories, funded through private investors based in Singapore and London.
- Apta has acquired from Fujitsu a strong technology platform which allows the company to make libraries of unique modified DNA called Seligo which have potential application in diagnostic, immunotherapeutics and antibody-drug conjugate fields where they can replace antibodies.
- Recruited and established the management team and laboratory
- Working with investors to develop the corporate strategy going forward.
- Initiated a shift from a technology company to a product based company focusing on applications.
- Developed collaborations with universities and companies
- Worked with partners to successfully obtain a large H2020 grant to develop next generation antibiotics and antivirals.
- In role of QA/RA Director oversaw ISO13485/9001 certification.

02/2012-06/2013

Title: **Chief Executive Officer**

Company: Dx Assays pte Ltd

- Dx is a Singapore based joint venture between the Singapore Government investment company and QIAGEN.
- Dx carries out contract research and development of molecular and companion diagnostics for a range of customers from large multinationals to small start ups and hospitals but primarily conducts development work for QIAGEN.
- Dx was wound down successfully in June 2013 following completion of all R&D projects and all investments returned to the shareholders.

10/2006- 6/2011

Title: **Executive Director/Chief Business Officer/Executive Chairman**

Company: Myconostica Ltd

- Raised £9.6M which allowed the company to, starting from scratch to establish itself as the leading fungal molecular diagnostic company winning awards for innovation
 - Launch three CE marked IVD with year on year positive sales growth

- Launch a novel microarray product for the research market
- Established distribution strategy and network
- Negotiated corporate partnerships with global industry players
- Oversaw sale of company to Lab21

02/2005 to 03/2006

Title: **Chief Executive Officer**

Company: Enigma Diagnostics Ltd.,

First CEO and established the future direction of the company..

02/2000 to 02/2005

Title: **Managing Director/CEO**

Company: Hammersmith Imanet Ltd, London

- Oversaw privatisation of academic centre of excellence and integration within parent company.
- Created viable mixed revenue stream business model to convert academic centre to commercial enterprise including commercial contracts with major pharma companies and diagnostic products to hospitals resulting in a cash neutral position in year 1 from a £2M loss. Remit was to run business on cash neutral basis to benefit all shareholders both Amersham and MRC.
- The business model was then rolled out to other centres in Uppsala and Turku and served as the PET research and clinical capability of Amersham/GE.
- Oversaw large capital investment programme which was completed on budget and on time.

09/94 to 02/2000

Title: **Chief Executive Officer/General Manager**

Company: Resolution Pharmaceuticals, Canada

06/88 to 09/94

Title: Various roles including **Director, New Business, Nordion Europe SA**
Managing Director, Medgenix Ltd(UK), Manager, In Vivo Products, Director R&D.

Company: Medgenix Diagnostics SA Belgium

Board Memberships

06/2008-present

Title: **Board Director and member of Audit Committee**

Organisation: Centre for Probe Development and Commercialisation

09/2006- 2014

Title: **Member, Scientific Advisory Board**

Company: Molecular Insight Inc.

05/04 to 01/10

Title: **Non Executive Director**

Company: Abcellute Ltd.

Academic Posts

01/83 to 06/88

Title: **Lecturer in Physical Chemistry**

University: Loughborough University of Technology,

01/81 to 01/83

Title: **Lecturer in Inorganic Chemistry**

University: Chelsea College
University of London,

09/79 to 01/81

Title: **Senior Scientific Officer**

Organisation: AERE Harwell

LANGUAGES:ENGLISH/FRENCH

QUALIFICATIONS :

B.Sc CHEMISTRY, 1ST CLASS
IMPERIAL COLLEGE, LONDON

Several prizes as including Frank Hatton Prize as top student in graduate year
Ph.D. INORGANIC CHEMISTRY, IMPERIAL COLLEGE, LONDON
Supervisor: Sir Geoffrey Wilkinson, Nobel Laureate

APPOINTMENTS AND MEMBERSHIPS

Fellow, Royal Society of Chemistry

Member, Radiochemistry Group committee, 2004-2010

Member, Society of Nuclear Medicine,

Member, Radiopharmaceutical Sciences Group committee 2001-3

Visiting fellow, Harvard University 1987-88, Massachusetts Institute of Technology
1986,

Adjunct Professor, McMaster University, 1997-2000

Visiting Professor, Faculty of Medicine, Imperial College, 2003-5

Expert for EU Framework 6 programme on cancer diagnosis, 2006

Advisor to A*Star Diagnostic HUB programme 2014-2016

Member British In Vitro Diagnostics Association working parties on External Affairs
and Procurement

Book: Medical Applications of Coordination Chemistry published 2007

PATENTS: >20 US Patents published or in prosecution

PUBLICATIONS: >90 Scientific Publications